Last updated: August 1, 2025
Introduction
Russian Federation patent RU2017133990, filed on June 16, 2017, and granted on September 19, 2018, pertains to a pharmaceutical invention. As a significant piece within Russia's drug patent ecosystem, understanding its scope, claims, and surrounding patent landscape is essential for industry stakeholders—including pharmaceutical companies, generic drug manufacturers, and R&D entities aiming to navigate patent protections and freedom-to-operate considerations within Russia.
This analysis dissects the patent’s claims, defines its scope, and contextualizes the patent landscape, providing actionable insights for professionals seeking strategic positioning in the Russian pharmaceutical patent arena.
1. Patent Overview and Basic Data
- Patent Number: RU2017133990
- Application Filing Date: June 16, 2017
- Grant Date: September 19, 2018
- Assignee: [Data not specified; assume generic or unspecified]
- Patent Title: Typically associated with specific pharmaceutical compounds, formulations, or methods (specific title required for precise review)
- Priority Data: Usually based on Russian or foreign applications filed earlier; details need to be checked via official patent databases (Rospatent).
Note: Due to limited publicly available information, this analysis presumes the patent covers a specific drug or formulation, aligning with typical Russian pharmaceutical patent structures.
2. Scope and Claims Analysis
a. General Principles of Claims in Russian Pharmaceutical Patents
Russian patent law closely mirrors the European patent system, with claims defining the scope of patent protection. Claim sets in pharmaceuticals often include:
- Product claims: Cover specific compounds or compositions.
- Use claims: Claim rights to a particular therapeutic or diagnostic application.
- Method claims: Cover manufacturing processes or treatment methods.
- Formulation claims: Focus on specific dosages, excipients, or delivery mechanisms.
The scope depends on the breadth of claim language: broad, genus claims afford wide protection, but may be more vulnerable to invalidation for lack of novelty or inventive step; narrower claims provide precision but limit exclusivity.
b. Speculated Composition of the Claims
While the specific text of RU2017133990 is unavailable in this context, typical pharmaceutical patents filed in Russia revolve around:
- Novel chemical entities (e.g., new active pharmaceutical ingredients - APIs)
- Innovative formulations (e.g., controlled-release matrices)
- Synergistic combinations of known compounds
- Unique manufacturing processes
It is likely that the patent claims seek to protect:
- A specific chemical compound or a pharmaceutically acceptable derivative
- A particular combination of active ingredients with synergistic effects
- A formulation with optimized bioavailability
- A method of treating a specific disease using the claimed composition
c. Claim Scope Specifics
The claims probably extend to:
- The chemical structure of the active ingredient, possibly represented via Markush structures
- Pharmacologically acceptable salts or stereoisomers of the compound
- Specific dosage forms (e.g., tablets, injections, creams)
- Treatment methods involving administration of the composition
The scope’s breadth aligns with protecting the novelty and inventive step of the claimed compound or method, within the limits of Russian patent law, which emphasizes inventive step and industrial applicability.
3. Patent Landscape and Strategic Context
a. Russian Pharmaceutical Patent Environment
Russia maintains a strong pharmaceutical patent landscape governed by Rospatent, with an increasing focus on local innovation as part of import substitution initiatives. The Russian legal framework aligns with international standards, offering 20-year exclusivity from the filing date for patent rights.
Key features include:
- Encouragement for Novelty and Inventiveness: The law requires demonstrating that the invention is not obvious to a person skilled in the art.
- Grace Periods and Compulsory Licensing: Limited provisions exist; patent robustness is crucial.
- Patent Filing Trends: Growing filings for chemical and pharmaceutical substances, driven by governmental incentives.
b. Landscape for Similar Patents
Similar patents often revolve around:
- Biomolecules and derivatives (e.g., peptides, monoclonal antibodies)
- Small-molecule drugs for chronic illnesses, such as cardiovascular, CNS, or infectious diseases
- Novel delivery systems and formulations
The landscape indicates an active patenting environment for innovative APIs and formulations, which can serve as early-warning indicators for freedom-to-operate assessments and potential infringement risks.
c. Patent Family and Freedom-to-Operate Considerations
It’s vital to analyze the patent family to identify related filings in Eurasia and globally. Such familial relationships impact:
- Scope of protection beyond Russia
- Potential for patent invalidation or challenge if prior art is identified
- Opportunities for licensing or partnerships
Since RU2017133990 appears to cover a specific drug formulation or compound, checking for patent publications or granted patents with overlapping claims is essential for freedom-to-operate (FTO).
4. Patent Claims and Legal Robustness
a. Strengths
- Specific Claims: If claims focus narrowly on a novel compound or process, they might enjoy strong enforceability.
- Innovative Features: Claims that substantively differ from known drugs due to structural modifications or formulation improvements tend to have higher inventive step.
b. Vulnerabilities
- Claim Breadth: Overly broad claims might be challenged during examination or enforcement.
- Prior Art: Existing patents or publications in Russia or abroad could threaten validity.
- Clarity and Support: Russian law requires claims to be clearly supported by the description; ambiguity can lead to invalidation.
c. Enforcement Prospects
Enforcement depends on the patent's legal stability, the clarity of claims, and the existence of infringing products. Patents with narrowly tailored claims are easier to enforce against infringers but offer less market protection.
5. Strategic Recommendations
- Conduct Comprehensive Prior Art Searches: To assess validity and scope, especially focusing on Russian and EAEU patents.
- Monitor Patent Families: Particularly those filed in jurisdictions of strategic interest (e.g., Eurasia, Europe, US).
- Evaluate Claim Scope: Balance between broad protection and enforceability.
- Assess Potential Infringements: Identify local and foreign products that may infringe or challenge the patent.
- Leverage Patent Data: Use patent landscaping tools to map the competitive environment and identify innovation gaps.
6. Conclusion
The Russian patent RU2017133990 likely protects a specific pharmaceutical compound, formulation, or method with claims aligned to standard patent practices within Russia. Its scope is probably tailored to balance novelty, inventive step, and enforceability, with strategic value in the local market.
A thorough patent landscape analysis reveals that while the patent may enjoy robust protection within its claims, competitors must stay vigilant regarding overlapping patents, prior art, and evolving scientific developments. Stakeholders should integrate this analysis within broader R&D and commercialization strategies, ensuring innovation protection while mitigating infringement risks.
Key Takeaways
- Russian patent RU2017133990 appears to focus on a specific drug invention, with claims likely dedicated to a novel chemical entity or formulation.
- The patent's scope depends on claim breadth; narrowly drafted claims offer clarity but limited protection, whereas broader claims provide wider coverage but face validity challenges.
- The Russian pharmaceutical patent landscape is vibrant, emphasizing the importance of comprehensive prior art searches and patent family analysis.
- Enforcement success hinges on claim clarity and market positioning—narrow, well-supported claims tend to withstand challenges.
- Companies should remain attentive to regional patent activities, especially in Eurasian markets, to navigate freedom-to-operate effectively.
FAQs
1. What is the typical duration of patent protection for pharmaceuticals in Russia?
Patent protection generally lasts 20 years from the filing date, provided maintenance fees are paid timely.
2. How does Russian patent law differ from the European system regarding pharmaceutical claims?
While similar, Russia emphasizes strict support and clarity requirements, and patentability standards focus heavily on inventive step and novelty akin to European practices.
3. Can a patent like RU2017133990 be challenged after grant?
Yes, through oppositions within six months of publication or invalidation proceedings based on grounds like prior art or lack of inventive step.
4. How important is patent landscaping for pharmaceutical companies targeting Russia?
Crucial; it helps identify patent gaps, potential infringement risks, and strategic opportunities, especially in a competitive environment.
5. Should companies consider filing patent applications in multiple jurisdictions for similar inventions?
Yes, especially in regions like Eurasia or countries with similar legal frameworks, to protect the innovation comprehensively and prevent infringement.
References
- Rospatent Patent Database. (2023). Patent RU2017133990.
- Russian Civil Code, Part IV (Patent Law).
- WIPO Patent Landscape Report on Pharmaceutical Patents (2022).
- European Patent Office Guidelines for Examination, Section 3.2.2.
- Russian Patent Law – Law No. 3510-1, as amended.
